Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02619617 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT02619617: Clinical Trial Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT02619617 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02619617, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.
Primary Outcome
Defined as very severe, severe, or moderate pain before dosing that becomes mild or nil at 30 minutes post-dosing
Interventions
- DRUG Placebo
- DRUG SOM230
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-10-31 |
| Est. Completion | 2018-09-25 |
| Phase | Phase 2 |
Why NCT02619617 stopped before completion
NCT02619617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02619617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02619617 about?
NCT02619617 is a clinical study titled "Safety and Efficacy Study of SOM230 s.c. in Cluster Headache". The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.
What is the current status of trial NCT02619617?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2016-10-31. Estimated completion is 2018-09-25.
What interventions are being tested in trial NCT02619617?
The interventions under investigation include: Placebo (DRUG), SOM230 (DRUG).
Who is sponsoring clinical trial NCT02619617?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02619617's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI